Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020

  • ID: 3957528
  • Report
  • Region: Global
  • 98 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • Avaxia Biologics
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Neovacs
  • MORE
About Autoimmune and Inflammatory Immunomodulators

Immunomodulators are the drugs that help to regulate the immune system. These drugs either stimulate the weak immune systems or moderate the overactive immune systems. Though many drugs are available in the market, there still exists a huge unmet need in the autoimmune and inflammatory immunomodulators market as there are no medicines that provide complete cure to some diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn’s disease.

The analysts forecast the global autoimmune and inflammatory immunomodulators market to grow at a CAGR of 7.01% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global autoimmune and inflammatory immunomodulators market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AbbVie
- Johnson & Johnson
- Amgen
- F. Hoffmann-La Roche
- Pfizer

Other prominent vendors
- AstraZeneca
- Avaxia Biologics
- Biogen Idec
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Eli Lilly
- Enlivex Therapeutics
- Gilead Sciences
- Immune Pharmaceuticals
- Merck
- Mitsubishi Tanabe Pharma
- Neovacs
- Prometheus Laboratories
- Sandoz
- Sanofi
- Swedish Orphan Biovitrum
- Takeda Pharmaceuticals
- UCB

Market drivers
- Development of novel therapies using innovative technologies.
- For a full, detailed list, view the full report

Market challenges
- Discontinuation of drugs under development leading to substantial loss in revenue.
- For a full, detailed list, view the full report

Market trends
- Advent of biosimilars expected to improve the treatment rates.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Avaxia Biologics
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Neovacs
  • MORE
Part 01: Executive summary
  • Highlights
Part 02: Scope of the report
  • Market overview
  • Top-vendor offerings
Part 03: Market research methodology
  • Research methodology
  • Economic indicators
Part 04: Introduction
  • Key market highlights
Part 05: Autoimmune and inflammatory diseases
  • Rheumatoid arthritis
  • IBD
  • Top immunomodulators for rheumatoid arthritis and IBD
Part 06: Pipeline portfolio

Part 07: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
Part 08: Market segmentation by type of disease
  • Global rheumatoid arthritis immunomodulators market
  • Global IBD immunomodulators market
Part 09: Market segmentation by molecule type
  • Global autoimmune and inflammatory biologic immunomodulators market
  • Global autoimmune and inflammatory small molecule immunomodulators market
Part 10: Geographical segmentation
  • Global autoimmune and inflammatory immunomodulators market by geography 2015-2020
  • Autoimmune and inflammatory immunomodulators market in Americas
  • Autoimmune and inflammatory immunomodulators market in EMEA
  • Autoimmune and inflammatory immunomodulators market in APAC
Part 11: Market drivers
  • Strong adoption of TNF-alpha inhibitors and B-cell inhibitors
  • Development of novel therapies using innovative technologies
  • Improved diagnostic tools increase the treatment-seeking population
Part 12: Impact of drivers

Part 13: Market challenges
  • Discontinuation of drugs under development leading to substantial loss of revenue
  • Growing popularity of alternative treatment procedures hinders the market growth
  • Adverse effects of the drugs
Part 14: Impact of drivers and challenges

Part 15: Market trends
  • Emergence of oral agents likely to improve patient outcomes
  • Advent of biosimilars expected to improve the treatment rates
  • Focus on regenerative medicines
  • Strategic alliances and acquisitions
Part 16: Vendor landscape
  • Competitive scenario
  • Other prominent vendors
Part 17: Key vendor analysis
  • AbbVie
  • Johnson & Johnson
  • Amgen
  • F. Hoffmann-La Roche
  • Pfizer
Part 18: Appendix
  • List of abbreviations
Part 19: About the Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Different classes of immunosuppressant drugs based on their mechanism of action
Exhibit 03: Key buying criteria for global autoimmune and inflammatory immunomodulators market 2015
Exhibit 04: Key customer segments of autoimmune and inflammatory immunomodulators market
Exhibit 05: Etiology of autoimmune diseases
Exhibit 06: Pipeline portfolio: Rheumatoid arthritis immunomodulators
Exhibit 07: Pipeline portfolio: Ulcerative colitis immunomodulators
Exhibit 08: Pipeline portfolio: Crohn's disease immunomodulators
Exhibit 09: Global autoimmune and inflammatory immunomodulators market snapshot: Developed and emerging markets 2015
Exhibit 10: Factors influencing global autoimmune and inflammatory immunomodulators market
Exhibit 11: Approval and patent expiries of top-selling biologics
Exhibit 12: Impact of factors affecting the market 2015 and 2020
Exhibit 13: Global autoimmune and inflammatory immunomodulators market 2015-2020 ($ billions)
Exhibit 14: Five forces analysis
Exhibit 15: Segmentation of global autoimmune and inflammatory immunomodulators by type of disease based on revenue 2015
Exhibit 16: Global autoimmune and inflammatory immunomodulators market by disease type 2015-2020
Exhibit 17: Global rheumatoid arthritis immunomodulators market 2015-2020 ($ billions)
Exhibit 18: Opportunities across rheumatoid arthritis industry
Exhibit 19: Global IBD immunomodulators market 2015-2020 ($ billions)
Exhibit 20: Global IBD therapeutics market segmentation growth lifecycle analysis
Exhibit 21: Global IBD immunomodulators market by disease type 2015-2020
Exhibit 22: Global ulcerative colitis immunomodulators market 2015-2020 ($ billions)
Exhibit 23: Global Crohn's disease immunomodulators market 2015-2020 ($ billions)
Exhibit 24: Comparative graph of global autoimmune and inflammatory immunomodulators market by molecule type ($ billions)
Exhibit 25: Global autoimmune and inflammatory biologic immunomodulators market 2015-2020 ($ billions)
Exhibit 26: Biologicals approvals by the US FDA
Exhibit 27: Global rheumatoid arthritis biologic immunomodulators market 2015-2020 ($ billions)
Exhibit 28: Global IBD biologic immunomodulators market 2015-2020 ($ billions)
Exhibit 29: Global autoimmune and inflammatory small molecule immunomodulators market 2015-2020 ($ billions)
Exhibit 30: Global autoimmune and inflammatory immunomodulators market by geography 2015-2020
Exhibit 31: Global autoimmune and inflammatory immunomodulators market segmentation by geography 2015-2020 ($ billions)
Exhibit 32: Global share of autoimmune and inflammatory immunomodulators market by geography 2015
Exhibit 33: Global autoimmune and inflammatory immunomodulators market segmentation by region: Market growth lifecycle analysis 2015
Exhibit 34: Global autoimmune and inflammatory immunomodulators market: Country analysis based on revenue and growth rate
Exhibit 35: Opportunity analysis of autoimmune and inflammatory immunomodulators market in Americas
Exhibit 36: Autoimmune and inflammatory immunomodulators market in Americas 2015-2020 ($ billions)
Exhibit 37: Opportunity analysis of autoimmune and inflammatory immunomodulators market in EMEA
Exhibit 38: Autoimmune and inflammatory immunomodulators market in EMEA 2015-2020 ($ billions)
Exhibit 39: Opportunity analysis of autoimmune and inflammatory immunomodulators market in APAC
Exhibit 40: Autoimmune and inflammatory immunomodulators market in APAC 2015-2020 ($ billions)
Exhibit 41: Sales performance of key TNF-alpha inhibitors and B-cell inhibitors ($ billions)
Exhibit 42: Key vendors: Developing novel therapies
Exhibit 43: Key developments leading to improved diagnostics
Exhibit 44: Impact of drivers
Exhibit 45: List of few immunomodulators that were discontinued from development or market
Exhibit 46: CAM therapies for rheumatoid arthritis
Exhibit 47: Usage of CAM therapies in US adults
Exhibit 48: List of CAM therapies and items used in Crohn's disease and ulcerative colitis
Exhibit 49: List of adverse side effects associated with rheumatoid arthritis
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Key marketed and pipeline oral agents
Exhibit 52: List of few biosimilars under development for various indications
Exhibit 53: List of few regenerative medicines under development for rheumatoid arthritis and IBD
Exhibit 54: Key deals in global immunomodulators market
Exhibit 55: Market share of key vendors 2015
Exhibit 56: Geographical presence of key vendors
Exhibit 57: Competitive scenario of global autoimmune and inflammatory immunomodulators market vendors 2015-2020
Exhibit 58: AbbVie: Strength assessment
Exhibit 59: AbbVie: Strategy assessment
Exhibit 60: AbbVie: Opportunity assessment
Exhibit 61: AbbVie: YoY growth and revenue of Humira 2013-2015 ($ billions)
Exhibit 62: Johnson & Johnson: Strength assessment
Exhibit 63: Johnson & Johnson: Strategy assessment
Exhibit 64: Johnson & Johnson: Opportunity assessment
Exhibit 65: Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
Exhibit 66: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 67: Amgen: Strength assessment
Exhibit 68: Amgen: Strategy assessment
Exhibit 69: Amgen: Opportunity assessment
Exhibit 70: Amgen: YoY revenue and growth rate of Enbrel (in the US and Canada) 2013-2015 ($ billions)
Exhibit 71: F. Hoffmann-La Roche: Strength assessment
Exhibit 72: F. Hoffmann-La Roche: Strategy assessment
Exhibit 73: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 74: F. Hoffmann-La Roche: YoY growth and revenue of MabThera/Rituxan for immunology segment 2013-2015 ($ billions)
Exhibit 75: F. Hoffmann-La Roche: YoY growth and revenue of Actemra/RoActemra for immunology segment 2013-2015 ($ billions)
Exhibit 76: Pfizer: Strength assessment
Exhibit 78: Pfizer: Strategy assessment
Exhibit 79: Pfizer: Opportunity assessment
Exhibit 80: Pfizer: Global autoimmune and inflammatory immunomodulators revenues 2014-2015 ($ billions)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • Avaxia Biologics
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Neovacs
  • MORE
New Report Released: - Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020

The author of the report recognizes the following companies as the key players in the global autoimmune and inflammatory immunomodulators market: AbbVie, Johnson & Johnson, Amgen, F. Hoffmann-La Roche, and Pfizer.

Other prominent vendors in the market are: AstraZeneca, Avaxia Biologics, Biogen Idec, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Enlivex Therapeutics, Gilead Sciences, Immune Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma, Neovacs, Prometheus Laboratories, Sandoz, Sanofi, Swedish Orphan Biovitrum, Takeda Pharmaceuticals, and UCB.

Commenting on the report, an analyst from the research team said: “One of latest trends in the market is emergence of oral agents likely to improve patient outcomes. The advent of oral agents in the treatment of rheumatoid arthritis and IBD are expected to have a positive impact on the market growth. For instance, JAK inhibitors such as Xeljanz are expected to become standard therapies in the future, owing to the reduced complications during the administration of drug. Many individuals are reluctant to use injectable medications. Therefore, vendors are increasingly focusing on developing oral agents for the treatment of rheumatoid arthritis. For example, in February 2016, Pfizer received the US FDA approval of Xeljanz XR (tofacitinib citrate), an oral JAK inhibitor, for the treatment of rheumatoid arthritis. As there is an increased need for oral therapies, the new product will substantially fuel the market growth in the future.”

According to the report, one of the primary drivers in the market is strong adoption of TNF-alpha inhibitors and B-cell inhibitors. The physicians prefer to adopt TNF-alpha inhibitors and B-cell inhibitors, owing to their established clinical profiles. For instance, AbbVie's Humira, targeted at autoimmune and other inflammatory indications, reported a worldwide revenue of approximately $14 billion in 2015, indicating an approximate growth of 12% year-on-year (YoY). The strong growth of Humira is attributed to the increasing prescription volume across various therapy areas, including rheumatoid arthritis and IBD. Also, TNF-alpha inhibitors such as Cimzia are posting substantial revenues owing to the increased adoption rates. Cimzia, a treatment for rheumatoid arthritis and Crohn's disease and other autoimmune diseases, reported revenue of $1.2 billion, indicating a YoY growth of 36% (base currencies).

Further, the report states that one major challenge in the market is discontinuation of drugs under development leading to substantial loss of revenue. Discontinuation of the drugs under development or from the market after its launch due to non-satisfactory safety or efficacy result is a major challenge for the market. Discontinuation in the late stages of development or from the market will lead to a heavy loss in revenues because of the high R&D and marketing costs invested by the company. Discontinuation of rheumatoid arthritis and IBD drugs is high as the drug target is not properly understood before the drug trial commences. Also, the drugs are sometimes discontinued at the later stages of the trial as unacceptable adverse effects appear on the body.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- AbbVie
- Amgen
- AstraZeneca
- Avaxia Biologics
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly
- Enlivex Therapeutics
- F. Hoffmann-La Roche
- Gilead Sciences
- Immune Pharmaceuticals
- Johnson & Johnson
- Merck
- Mitsubishi Tanabe Pharma
- Neovacs
- Pfizer
- Prometheus Laboratories
- Sandoz
- Sanofi
- Swedish Orphan Biovitrum
- Takeda Pharmaceuticals
- UCB
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll